Tonix Pharmaceuticals Publishes Presentation on TNX-4800 for Lyme Disease Prevention

PUBT · 19h ago
Tonix Pharmaceuticals Publishes Presentation on TNX-4800 for Lyme Disease Prevention
  • Tonix Pharmaceuticals published a medical research presentation on TNX-4800 for Lyme disease prevention in the U.S.
  • A planned adaptive Phase 2 field study remains subject to FDA agreement on the final protocol.
  • Investigational product manufacturing is on track for the first quarter of 2027.
  • Completed Phase 1 testing showed no significant clinical or laboratory safety signals; human preventive efficacy remains unestablished.
  • The two-dose regimen targets protection within two days for at least six months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.